Adverse Effects Associated With Hypophosphatemia

Panelists discuss how hypophosphatemia can cause both acute effects like muscle weakness and confusion and chronic complications such as osteomalacia and metabolic disturbances, potentially impacting patients’ mobility, energy levels, and overall quality of life if not properly monitored and managed.

EP: 1.Background and Causes of Iron Deficiency Anemia

EP: 2.Pathophysiology of Iron Deficiency Anemia

EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia

EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia

EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis

EP: 6.Oral vs IV Iron in Clinical Practice

EP: 7.FDA-Approved IV Iron Formulations

EP: 8.Factoring in Safety Considerations With IV Iron Products

Now Viewing

EP: 9.Adverse Effects Associated With Hypophosphatemia

EP: 10.Clinical Impact of Hypophosphatemia

EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron

EP: 12.Adherence and Time Spent Receiving IV Iron Infusions

EP: 13.Step Edits Associated with IV Iron Therapies

EP: 14.The Future of IV Iron Administration

EP: 15.Closing Thoughts on Iron Deficiency Anemia

Video content above is prompted by the following:

• What are the short- and long-term effects of hypophosphatemia? How do these impact patients’ daily lives?

Related Videos

Related Content

Advertisement

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils

Brooke McCormick

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.

June 6th 2025

5 Key FDA Approval Dates Mark a Milestone-Filled May

Brooke McCormick

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Related Content

Advertisement

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils

Brooke McCormick

Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.

June 6th 2025

5 Key FDA Approval Dates Mark a Milestone-Filled May

Brooke McCormick

In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.